Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia

References

• AlessandrinoEPAmadoriSBarosiGEvidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of HematologyHaematologica200287128630612495903
   PubMed Web of Science ®Google Scholar
• ArcasoyMOAminKChouSCErythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxiaClin Cancer Res20051120715671524
   PubMed Web of Science ®Google Scholar
• AuerbachMBallardHTroutJRIntravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trialJ Clin Oncol2004221301715051778
   PubMed Web of Science ®Google Scholar
• BalleariERossiEClavioMErythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre studyAnn Hematol2006851748016408206
   PubMed Web of Science ®Google Scholar
• BeguinYVernaMLooMErythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin productionBr J Haematol199282648531482651
   PubMed Web of Science ®Google Scholar
• BeguinYErythropoiesis and erythropoietin in multiple myelomaLeuk Lymphoma19951841221
   Google Scholar
• BocciaRMalikIARajaVDarbepoetin alpha administered every three weeks is effective for the treatment of chemotherapy-induced anemiaOncologist20061144091716614237
   PubMedGoogle Scholar
• BohliusJLangensiepenSSchwarzerGRecombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysisJ Natl Cancer Inst2005974899815812074
   PubMed Web of Science ®Google Scholar
• BohliusJWilsonJSeidenfeldJErythropoietin or darbepoetin for patients with cancerCochrane Database Syst Rev20063CD00340716856007
   PubMedGoogle Scholar
• BokemeyerCAaproMSCourdiAEORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerEur J Cancer20044022011615454245
   PubMed Web of Science ®Google Scholar
• BrenAKandusAVarlJA comparison between epoetin omega and epoetin alpha in the correction of anemia in hemodialysis patients: a prospective, controlled crossover studyArtif Organs20022691711879235
   PubMed Web of Science ®Google Scholar
• CanonJLVansteenkisteJGyörgy BodokyGRandomized, double-blind, active-controlled trial of every-3-week darbepoetin alpha for the treatment of chemotherapy-induced anemiaJ Natl Cancer Inst2006982738416478746
   PubMed Web of Science ®Google Scholar
• CazzolaMBeguinYKloczkoJOnce-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin productionBr J Haematol20031223869312877665
   PubMed Web of Science ®Google Scholar
• CellaDThe Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigueSemin Hematol199734Suppl.213199253779
   PubMed Web of Science ®Google Scholar
• ChangJCoutureFYoungSWeekly epoetin alpha maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapyJ Clin Oncol200523259760515452188
   PubMed Web of Science ®Google Scholar
• ChesonBDGreenbergPLBennettJMClinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood20061084192516609072
   PubMed Web of Science ®Google Scholar
• DeicherRHorlWHDifferentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney diseaseDrugs20046449950914977387
   PubMed Web of Science ®Google Scholar
• EgrieJCBrowneJKDevelopment and characterization of novel erythropoiesis stimulating protein (NESP)Br J Cancer200184Suppl.131011308268
   PubMed Web of Science ®Google Scholar
• ElliottSBusseLBassMEAnti-Epo receptor antibodies do not predict Epo receptor expressionBlood20061071892516249375
   PubMed Web of Science ®Google Scholar
• ElliottSEgrieJBrowneJControl of rHuEPO biological activity: the role of carbohydrateExp Hematol20043211465515588939
   PubMed Web of Science ®Google Scholar
• GabriloveJLCleelandCSLivingstoneRBClinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosingJ Clin Oncol20011928758211387360
   PubMed Web of Science ®Google Scholar
• GlaspyJHenryDPatelREffects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alpha: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alphaEur J Cancer2005411140915911237
   PubMed Web of Science ®Google Scholar
• GlaspyJAJadejaJSJusticeGDarbepoetin alpha given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapyBr J Cancer2002872687612177793
   PubMed Web of Science ®Google Scholar
• HarperPLittlewoodTAnemia of cancer: impact on patient fatigue and long-term outcomeOncology200569suppl 22716244504
   PubMed Web of Science ®Google Scholar
• HeatheringtonACSchullerJMercerAJPharmakokinetics of novel erythropoiesis stimulating protein (NESP) in cance patients: preliminary reportBr J Cancer200184suppl.1111611308269
   PubMed Web of Science ®Google Scholar
• HedenusMAdrianssonMSan MiguelJEfficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled studyBr J Haematol200312239440312877666
   PubMed Web of Science ®Google Scholar
• Hellstrom-LindbergEAhlgrenTBeguinYTreatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patientsBlood19989268759639501
   PubMed Web of Science ®Google Scholar
• HenkeMLaszigRRubeCErythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo controlled trialLancet200336212556014575968
   PubMed Web of Science ®Google Scholar
• HenryDHGordanLCharuVRandomized, open-label comparison of epoetin alpha extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemiaCurr Med Res Opin20062214031316834839
   PubMed Web of Science ®Google Scholar
• HerringtonJDDavidsonSLTomitaDKUtilization of darbepoetin alpha and epoetin alpha for chemotherapy-induced anemiaAm J Health Syst Pharm200562546215658073
   PubMed Web of Science ®Google Scholar
• [ICSG] Italian Cooperative Study Group for rHuEpo in Myelodysplastic SyndromesA randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromesBr J Haematol1998103107049886322
   PubMedGoogle Scholar
• KotasekDStegerGFaughtWDarbepoetin alpha administered every 3 weeks alleviated anaemia in patients with solid tumors receiving chemotherapy; results of a double-blind, placebo-conrolled, randomised studyEur J Cancer20033920263412957457
   PubMed Web of Science ®Google Scholar
• Leyland-JonesBBEST Investigators and Study GroupBreast cancer trial with erythropoietin terminated unexpectedlyLancet Oncol200344596012901958
   PubMed Web of Science ®Google Scholar
• LittlewoodTJBajettaENortierJWEpoetin alpha study group. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trialJ Clin Oncol20011928657411387359
   PubMed Web of Science ®Google Scholar
• LittlewoodTJKallichJDSan MiguelJEfficacy of darbepoetin alpha in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignanciesJ Pain Symptom Manage200633172516632079
   PubMedGoogle Scholar
• LittlewoodTJZagariMPallisterCBaseline and early treatment factors are not clinically useful for predictingindividual response to erythropoietin in anemic cancer patientsOncologist200389910712604736
   PubMed Web of Science ®Google Scholar
• LudwigHVan BelleSBarrett-LeePThe European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEur J Cancer200440229330615454256
   PubMed Web of Science ®Google Scholar
• MannoneLGardinCQuarreMCHigh-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II studyBr J Haematol20061335131916681638
   PubMed Web of Science ®Google Scholar
• MustoPLanzaFBalleariEDarbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromesBr J Haematol2005128204915638854
   PubMed Web of Science ®Google Scholar
• [NCCN] National Comprehensive Cancer NetworkClinical practice guidelines in oncology, v.2.2006. Cancer and treatment-related anemia [online]2006 Accessed on 25 Sept 2006. URL: http:/www.enccn.com/professionals/physician_gls/PDF/anemia.pdf
   Google Scholar
• OsterborgABrandbergYMolostovaVRandomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignanciesJ Clin Oncol20022024869412011126
   PubMed Web of Science ®Google Scholar
• OsterborgAHellmannAJuan Luis SteegmannJLCERA (Continuous Erythropoietin Receptor Activator): Dose-response trial of subcutaneous (SC) administration once every 3 weeks (Q3W) to patients with aggressive non-Hodgkin’s lymphoma and anemia receiving chemotherapy [abstract]Blood200410446th meeting of the American Society of HematologyDecember 4–7San Diego, CA4225
   Google Scholar
• PattonJReevesTWallaceJEffectiveness of Darbepoetin alpha versus Epoetin alpha in patients with chemotherapy-induced anemia treated in clinical practiceOncologist20049451815266098
   PubMed Web of Science ®Google Scholar
• PattonJFSullivanTMunYA retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alpha for epoetin alpha in anemic patients with myelodysplastic syndromeJ Support Oncol200534192616350429
   PubMedGoogle Scholar
• RizzoJDLichtinAEWoolfSHUse of erythropoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of HematologyJ Clin Oncol200220408310712351606
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSYeeLKSenecalFMA randomized comparison of every-2-week darbepoetin alpha and weekly epoetin alpha for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancerOncologist2004969670715561813
   PubMed Web of Science ®Google Scholar
• SenecalFMYeeLGabrailNTreatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alpha 200 microg every 2 weeks versus epoetin alpha 40,000 U weeklyClin Breast Cancer200564465416381629
   PubMedGoogle Scholar
• ShashaDGeorgeMJLouisBOnce-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapyCancer2003981072912942577
   PubMed Web of Science ®Google Scholar
• SmithREJrJaiyesimiIAMezaLANovel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancerBr J Cancer200184Suppl.1243011308271
   PubMed Web of Science ®Google Scholar
• SmithREJrTchekmedyianNSChanDA dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancerBr J Cancer2003881851812799626
   PubMed Web of Science ®Google Scholar
• SteadRBLambertJWesselsDEvaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteersBlood20061081830416720830
   PubMed Web of Science ®Google Scholar
• TerposEMougiouAKouraklisAThe Greek MDS Study GroupProlonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patientsBr J Haematol20031181748012100145
   PubMedGoogle Scholar
• Vadhan-RajSMirtschingBCharuVAssessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alpha every two weeksJ Support Oncol20031131815352656
   PubMedGoogle Scholar
• VansteenkisteJPirkerRMassutiBDouble-blind, placebo-controlled, randomized phase iii trial of darbepoetin alpha in lung cancer patients receiving chemotherapyJ Natl Cancer Inst20029412112012189224
   PubMed Web of Science ®Google Scholar
• WaltzmanRCrootCJusticeGRRandomized comparison of epoetin alpha (40,000 U weekly) and darbepoetin alpha (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapyOncologist2005106425016177289
   PubMed Web of Science ®Google Scholar
• WitzigTESilbersteinPTLoprinziCLPhase III, randomized, double-blind study of epoetin alpha compared with placebo in anemic patients receiving chemotherapyJ Clin Oncol20052326061715452187
   PubMed Web of Science ®Google Scholar